Hepatocellular Carcinoma (HCC) is rising in incidence worldwide, especially in areas endemic for chronic viral hepatitis. Distant metastases are common especially in lungs and bones. Subcutaneous or mucosal metastases, however, are rare. We report a case of both mucosal and subcutaneous metastases in the same patient.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the ninth in women 1 worldwide and has an increased incidence in areas endemic for chronic viral hepatitis. The majority of HCCs present at an advanced stage and common sites of extra-hepatic metastases include the lungs, intraabdominal lymph nodes and bones. We report a case of gingival and subcutaneous metastasis from HCC.
CASE REPORT
The patient involved was a 48-year-old Chinese male who lived in Batam, Indonesia. He was a known hepatitis B carrier but did not have any evidence of liver cirrhosis. He was first diagnosed with HCC in 2010 in a private centre, when he presented with abdominal pain and was found to have an 8-cm tumour in the right lobe of the liver with an elevated alpha-foetoprotein (AFP) level of >9000 μg/L. He underwent transarterial chemo-embolisation followed by right hepatectomy in 2010. Histology confirmed the presence of a 9-cm moderately differentiated HCC with an adjacent 2.5-cm tumour. The presence of lymphovascular invasion was also noted. The surgical margins were free of tumour involvement. In February 2012, he was found to have a new left lung nodule on surveillance imaging; this was proven to be metastatic HCC, on biopsy.
He was started on thalidomide and capecitabine as he could not afford sorafenib due to personal financial constraints 2 . After two months, the AFP level decreased and there was complete response of the lung metastasis. However, new subcutaneous nodules were discovered over his right shoulder and in the gingiva. These lesions were excised and proven to be HCC metastases. In view of disease progression, thalidomide and capecitabine were discontinued. He was not on any systemic treatment until February 2013, when he developed multiple lung nodules and lymphadenopathy. It was at this stage that he first presented to us and was offered a clinical trial drug in view of good functional status and organ function. He was noted to have a subcentimetre nodule under the chin prior to initiation of the clinical trial. He continued on the trial till September 2013, when he was found to have progression of disease in the liver and skin.
Hepatocellular carcinoma is the second most common cause of death from cancer worldwide 1 . It often occurs in the background of cirrhosis, commonly caused by hepatitis B or C infection, or alcohol consumption. Therefore, HCC is more common in Asian countries where hepatitis B and C infections are endemic. Hepatocellular carcinoma is the fourth most common cause of cancer in Singaporean men and the third cause of cancerrelated deaths in men 3 . Extra-hepatic metastases in HCC occur in the advanced stages in about 30-50% of patients. The most common sites of extrahepatic metastasis are the lungs, followed by abdominal lymph nodes and bones 4 .
Head and neck or subcutaneous metastases from HCC are uncommon. Oral cavity or gingival metastases account for about 1% of malignant oral neoplasms 5 . Cutaneous or subcutaneous metastases that are not related to biopsy needle tracks are rare. To date, there are over 60 case reports in the literature of the presence of isolated metastasis involving tongue, gingiva, parotid gland, mandible and zygoma 6 . Young et al. reported a case of metastatic HCC presenting as a parotid swelling which was eventually proven to be metastatic HCC 7 . A retrospective analysis of autopsy reports of 31 patients with HCC revealed one case of skin and one of oral cavity metastasis 4 : these were the first manifestation of HCC in the individual patients. Isolated cases of cutaneous metastasis have also been reported, less commonly than oral cavity metastasis. Cutaneous metastases are often mistaken for pyogenic granuloma or haemangioma 4,7-9 . However, in these case reports, multiple uncommon sites have not been reported.
Hepatocellular carcinoma predominantly spreads via a haematogenous route. As such in most of the reported cases, including this case, patients often present with lung metastases prior to developing metastases in other unusual areas. Other modes of dissemination include portal venous and lymphatic spread. In patients without lung metastases, it is hypothesised that HCC spreads via the valveless vertebral venous plexus (Batson's plexus) allowing tumours in the lower part of the body to bypass the lungs to access the oral mucosa 6, 11 ; this postulation needs further investigation. As for non-iatrogenic cutaneous metastases, there does not seem to be a clear predisposing factor that contributes to the increased incidence.
Racial predilection seems to exist in development of metastases to skin and oral cavity. Almost 60% of such cases are reported in Asians 12 , although this may be a reflection of the increased incidence of HCC in the Asian population. Regarding oral cavity metastases, males appear to have an increased incidence, with a male: female ratio of 9:1 12 . With advancements in the treatment of HCC and patients having prolonged survival, more such cases may come to light.
One common presentation or complication that has been highlighted in reports of metastatic HCC in the oral cavity is bleeding 13, 14 . Metastatic HCC has a higher tendency to bleed, due to underlying coagulopathy and vascularity of the tumour itself. Bleeding in mucosal areas may potentially be difficult to control 10 . While systemic therapy should be the mainstay of care in metastatic disease, these local lesions can be palliated with either surgical resection or radiotherapy. Radiation treatment was found to have satisfactory results with low toxicity profile in patients with subcutaneous metastasis 15 . Huang et al. reported 83.3% partial response rate with radiotherapy to subcutaneous metastases from HCC 16 . Since expected survival with metastatic HCC is measured in months, a low-risk and effective procedure is required for good palliation of such mucosal or subcutaneous lesions. Whether HCC patients with subcutaneous and mucosal metastases have a different biology and outcome as compared to patients with other visceral metastases is not known. Metastatic HCC should be a consideration in patients with a history of HCC or risk factors for the disease and present with unexplained subcutaneous or mucosal lesions.
